BR112019018688A2 - derivados de imidazo[4,5-c] quinolina como inibidores de lrrk2 - Google Patents
derivados de imidazo[4,5-c] quinolina como inibidores de lrrk2 Download PDFInfo
- Publication number
- BR112019018688A2 BR112019018688A2 BR112019018688A BR112019018688A BR112019018688A2 BR 112019018688 A2 BR112019018688 A2 BR 112019018688A2 BR 112019018688 A BR112019018688 A BR 112019018688A BR 112019018688 A BR112019018688 A BR 112019018688A BR 112019018688 A2 BR112019018688 A2 BR 112019018688A2
- Authority
- BR
- Brazil
- Prior art keywords
- methyl
- imidazo
- quinoline
- chloro
- pyran
- Prior art date
Links
- 0 CC(C*1*=*C(COC)=C1)S* Chemical compound CC(C*1*=*C(COC)=C1)S* 0.000 description 10
- DHXVGJBLRPWPCS-UHFFFAOYSA-N C1CCOCC1 Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N CCN(C(C)C)C(C)C Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- XXSBUDAMUZHBRX-UHFFFAOYSA-N Cc1ncc(CC(O)=O)nc1 Chemical compound Cc1ncc(CC(O)=O)nc1 XXSBUDAMUZHBRX-UHFFFAOYSA-N 0.000 description 2
- WUPUVNVQRZOLKI-ABLWVSNPSA-N C(C1C=CC=CC1)OC[C@H]1OCCCC1 Chemical compound C(C1C=CC=CC1)OC[C@H]1OCCCC1 WUPUVNVQRZOLKI-ABLWVSNPSA-N 0.000 description 1
- ZHPKAPJNEIKPGV-UHFFFAOYSA-N CC(C1)OCCC1O Chemical compound CC(C1)OCCC1O ZHPKAPJNEIKPGV-UHFFFAOYSA-N 0.000 description 1
- UUEPRYDUKBGQPM-UHFFFAOYSA-N CC(OCc1ncc(CC(O)=O)nc1)=O Chemical compound CC(OCc1ncc(CC(O)=O)nc1)=O UUEPRYDUKBGQPM-UHFFFAOYSA-N 0.000 description 1
- FTEGDCQABRIUNQ-GQCTYLIASA-N CC/C(/C)=C/CN Chemical compound CC/C(/C)=C/CN FTEGDCQABRIUNQ-GQCTYLIASA-N 0.000 description 1
- PQVKXOHZURPQEV-UHFFFAOYSA-N CCC1NC(c2cc(Cl)ccc2NC2)=C2N1 Chemical compound CCC1NC(c2cc(Cl)ccc2NC2)=C2N1 PQVKXOHZURPQEV-UHFFFAOYSA-N 0.000 description 1
- MRISAQCVEWICGN-RKDXNWHRSA-N CCCC(O[C@H]1C[C@@H](C)OCC1)=O Chemical compound CCCC(O[C@H]1C[C@@H](C)OCC1)=O MRISAQCVEWICGN-RKDXNWHRSA-N 0.000 description 1
- PAQZWJGSJMLPMG-UHFFFAOYSA-N CCCP(OP(CCC)(O1)=O)(OP1(CCC)=O)=O Chemical compound CCCP(OP(CCC)(O1)=O)(OP1(CCC)=O)=O PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 1
- RAALGJJSGYJSAR-UHFFFAOYSA-N CNC[n]1ncnc1 Chemical compound CNC[n]1ncnc1 RAALGJJSGYJSAR-UHFFFAOYSA-N 0.000 description 1
- GGYQMMKITQQWED-UHFFFAOYSA-N COCC1C=CC=CC1 Chemical compound COCC1C=CC=CC1 GGYQMMKITQQWED-UHFFFAOYSA-N 0.000 description 1
- QOWBXWFYRXSBAS-UHFFFAOYSA-N COc1ccc(CN)c(OC)c1 Chemical compound COc1ccc(CN)c(OC)c1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 description 1
- MQOPUXINXNVMKJ-RXMQYKEDSA-N C[C@H](C1)OCCC1=O Chemical compound C[C@H](C1)OCCC1=O MQOPUXINXNVMKJ-RXMQYKEDSA-N 0.000 description 1
- KKEUHJVIIYOFFU-DGCLKSJQSA-N C[C@H](C1)OCC[C@H]1NCc(c(OC)c1)ccc1OC Chemical compound C[C@H](C1)OCC[C@H]1NCc(c(OC)c1)ccc1OC KKEUHJVIIYOFFU-DGCLKSJQSA-N 0.000 description 1
- ZHPKAPJNEIKPGV-PHDIDXHHSA-N C[C@H](C1)OCC[C@H]1O Chemical compound C[C@H](C1)OCC[C@H]1O ZHPKAPJNEIKPGV-PHDIDXHHSA-N 0.000 description 1
- NCRIYZINLLFUQN-VEDVMXKPSA-N C[C@H](CC1)OCC1c(c(C(F)(F)F)ccc1nc2)c1c(N)c2N Chemical compound C[C@H](CC1)OCC1c(c(C(F)(F)F)ccc1nc2)c1c(N)c2N NCRIYZINLLFUQN-VEDVMXKPSA-N 0.000 description 1
- AEVHCQGUOFFWAC-UHFFFAOYSA-N Cc(cc1)cc2c1ncc([N+]([O-])=O)c2Cl Chemical compound Cc(cc1)cc2c1ncc([N+]([O-])=O)c2Cl AEVHCQGUOFFWAC-UHFFFAOYSA-N 0.000 description 1
- HXMQKKQNWBSEBE-UHFFFAOYSA-N Cc1cnc(Cc2nc(cnc3c4cc(C(F)F)cc3)c4[nH]2)cn1 Chemical compound Cc1cnc(Cc2nc(cnc3c4cc(C(F)F)cc3)c4[nH]2)cn1 HXMQKKQNWBSEBE-UHFFFAOYSA-N 0.000 description 1
- DIPDMUBYEDDWKG-UHFFFAOYSA-N Nc(cnc(cc1)c2cc1Cl)c2NC1CCOCC1 Chemical compound Nc(cnc(cc1)c2cc1Cl)c2NC1CCOCC1 DIPDMUBYEDDWKG-UHFFFAOYSA-N 0.000 description 1
- JSWSNMRGRLUNDP-UHFFFAOYSA-O Nc1cnc(ccc(Cl)c2)c2c1[NH3+] Chemical compound Nc1cnc(ccc(Cl)c2)c2c1[NH3+] JSWSNMRGRLUNDP-UHFFFAOYSA-O 0.000 description 1
- NFNOAHXEQXMCGT-UHFFFAOYSA-N O=CCOCc1ccccc1 Chemical compound O=CCOCc1ccccc1 NFNOAHXEQXMCGT-UHFFFAOYSA-N 0.000 description 1
- PKVDTLZMQDBFOF-UHFFFAOYSA-N [O-][N+](c1cnc(ccc(Cl)c2)c2c1NC1CCOCC1)=O Chemical compound [O-][N+](c1cnc(ccc(Cl)c2)c2c1NC1CCOCC1)=O PKVDTLZMQDBFOF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762469756P | 2017-03-10 | 2017-03-10 | |
| US201862629152P | 2018-02-12 | 2018-02-12 | |
| PCT/IB2018/051439 WO2018163066A1 (en) | 2017-03-10 | 2018-03-06 | Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019018688A2 true BR112019018688A2 (pt) | 2020-04-07 |
Family
ID=61683855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019018688A BR112019018688A2 (pt) | 2017-03-10 | 2018-03-06 | derivados de imidazo[4,5-c] quinolina como inibidores de lrrk2 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11312713B2 (enExample) |
| EP (1) | EP3592741B1 (enExample) |
| JP (1) | JP7219223B2 (enExample) |
| KR (1) | KR102582626B1 (enExample) |
| CN (1) | CN111051304B (enExample) |
| AU (1) | AU2018230236B2 (enExample) |
| BR (1) | BR112019018688A2 (enExample) |
| CA (1) | CA3056030A1 (enExample) |
| IL (1) | IL269214B (enExample) |
| MX (1) | MX2019010756A (enExample) |
| SG (2) | SG10202110112TA (enExample) |
| TW (1) | TWI701246B (enExample) |
| WO (1) | WO2018163066A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3182162A1 (en) | 2020-05-06 | 2021-11-11 | Les Laboratoires Servier | New macrocyclic lrrk2 kinase inhibitors |
| TW202304935A (zh) | 2021-03-18 | 2023-02-01 | 法商施維雅藥廠 | 新穎的巨環lrrk2激酶抑制劑 |
| AU2023269061A1 (en) * | 2022-05-12 | 2024-11-14 | Interline Therapeutics, Inc. | Lrrk2 inhibitors |
| EP4522616A1 (en) * | 2022-05-12 | 2025-03-19 | Interline Therapeutics, Inc. | Lrrk2 inhibitors |
| CN115728413A (zh) * | 2022-11-09 | 2023-03-03 | 内蒙古帕默康创医疗仪器有限公司 | 舍曲林血药浓度的定量分析方法 |
| CN116879450A (zh) * | 2023-07-25 | 2023-10-13 | 江苏汉邦科技股份有限公司 | 一种利用超临界流体色谱系统分离纯化芦可替尼前体的方法 |
| CN118440041B (zh) * | 2024-07-02 | 2024-09-27 | 苏州凯瑞医药科技有限公司 | 一种手性4-氨基-3-羟基四氢吡喃的制备方法 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| IL73534A (en) * | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| CA1335996C (en) * | 1988-02-16 | 1995-06-20 | Susumu Takada | 2-substituted carbonylimidazo¬4,5-c|quinolines |
| US5389640A (en) * | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| ES2111065T5 (es) | 1991-04-16 | 2005-06-16 | Nippon Shinyaku Company, Limited | Procedimiento para producir una dispersion solida. |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
| ATE239797T1 (de) | 1993-01-25 | 2003-05-15 | Takeda Chemical Industries Ltd | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung |
| DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
| WO1998044955A1 (en) | 1997-04-09 | 1998-10-15 | Mindset Ltd. | Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| ATE364374T1 (de) | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| WO2001062801A2 (en) | 2000-02-24 | 2001-08-30 | Washington University | Humanized antibodies that sequester amyloid beta peptide |
| AU3976402A (en) | 2000-11-03 | 2002-06-03 | Proteotech Inc | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
| EP1432444A4 (en) | 2001-08-17 | 2005-11-02 | Lilly Co Eli | ANTI-BETA ANTIBODIES |
| US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| CA2501945A1 (en) | 2002-10-09 | 2004-04-22 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| WO2004110996A1 (en) | 2003-06-19 | 2004-12-23 | Pfizer Products Inc. | Nk1 antagonist |
| MY157827A (en) | 2003-06-27 | 2016-07-29 | 3M Innovative Properties Co | Sulfonamide substituted imidazoquinolines |
| WO2005025616A1 (ja) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | 抗体の用途 |
| AR046845A1 (es) * | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
| EP1720847A1 (en) | 2004-02-02 | 2006-11-15 | Pfizer Products Incorporated | Histamine-3 receptor modulators |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| CA2575663C (en) | 2004-07-30 | 2013-04-23 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
| WO2006069081A2 (en) | 2004-12-22 | 2006-06-29 | Washington University In St. Louis | USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY |
| UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
| EP1899296B1 (en) | 2005-06-22 | 2010-11-17 | Pfizer Products Inc. | Histamine-3 receptor antagonists |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| JP2009514846A (ja) | 2005-11-04 | 2009-04-09 | ファイザー・リミテッド | テトラヒドロナフチリジン誘導体 |
| WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
| WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| JP2009539762A (ja) | 2006-03-13 | 2009-11-19 | ファイザー・プロダクツ・インク | Ｈ３受容体のテトラリン拮抗薬 |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| BRPI0806473A2 (pt) | 2007-01-22 | 2011-09-27 | Pfizer Prod Inc | sal de tosilato de um composto terapêutico e composições farmacêuticas do mesmo |
| ITMI20070890A1 (it) | 2007-05-04 | 2008-11-05 | Sifi Spa | Composizioni oftalmiche per il trattamento della ipertensione oculare e del glaucoma |
| GB201008134D0 (en) | 2010-05-14 | 2010-06-30 | Medical Res Council Technology | Compounds |
| US8895581B2 (en) * | 2010-05-17 | 2014-11-25 | Boehringer Ingelheim International Gmbh | 1H-imidazo[4,5-c]quinolines |
| ES2524892T3 (es) | 2010-09-02 | 2014-12-15 | Glaxosmithkline Intellectual Property Development Limited | 2-(Benciloxi)benzamidas como inhibidores de LRRK2 quinasa |
| US9233977B2 (en) | 2010-10-29 | 2016-01-12 | Merck Sharp & Dohme Corp. | Leucine-rich repeat kinase enzyme activity |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| WO2013007768A1 (en) * | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| US20150218172A1 (en) | 2012-10-04 | 2015-08-06 | Pfizer Limited | Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors |
| WO2014060113A1 (en) * | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Novel kinase inhibitors |
| ITTO20130694A1 (it) * | 2013-08-14 | 2015-02-15 | Umbra Meccanotecnica | Giunto washpipe per un impianto di perforazione petrolifera |
| UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
| WO2016009297A1 (en) | 2014-07-18 | 2016-01-21 | Pfizer Inc. | Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators |
| WO2016108130A1 (en) | 2014-12-30 | 2016-07-07 | Sun Pharmaceutical Industries Limited | Topical pharmaceutical compositions comprising nebivolol for the treatment of diabetic wounds |
| KR102161364B1 (ko) * | 2015-09-14 | 2020-09-29 | 화이자 인코포레이티드 | LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체 |
| JP2019517580A (ja) | 2016-06-01 | 2019-06-24 | ハロルド・リチャード・ヘルストロムＨａｒｏｌｄ Ｒｉｃｈａｒｄ ＨＥＬＬＳＴＲＯＭ | 副交感神経薬および抗交感神経薬でのドライアイ疾患の処置 |
| US11161844B2 (en) * | 2017-03-10 | 2021-11-02 | Pfizer Inc. | Cyclic substituted imidazo[4,5-c]quinoline derivatives |
-
2018
- 2018-03-06 MX MX2019010756A patent/MX2019010756A/es unknown
- 2018-03-06 EP EP18711703.1A patent/EP3592741B1/en active Active
- 2018-03-06 CA CA3056030A patent/CA3056030A1/en active Pending
- 2018-03-06 WO PCT/IB2018/051439 patent/WO2018163066A1/en not_active Ceased
- 2018-03-06 US US16/492,558 patent/US11312713B2/en active Active
- 2018-03-06 SG SG10202110112T patent/SG10202110112TA/en unknown
- 2018-03-06 CN CN201880029989.5A patent/CN111051304B/zh active Active
- 2018-03-06 SG SG11201908322W patent/SG11201908322WA/en unknown
- 2018-03-06 JP JP2019549462A patent/JP7219223B2/ja active Active
- 2018-03-06 BR BR112019018688A patent/BR112019018688A2/pt not_active Application Discontinuation
- 2018-03-06 AU AU2018230236A patent/AU2018230236B2/en active Active
- 2018-03-06 KR KR1020197029735A patent/KR102582626B1/ko active Active
- 2018-03-07 TW TW107107734A patent/TWI701246B/zh active
-
2019
- 2019-09-09 IL IL269214A patent/IL269214B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018230236B2 (en) | 2022-05-19 |
| US11312713B2 (en) | 2022-04-26 |
| JP7219223B2 (ja) | 2023-02-07 |
| TW201900642A (zh) | 2019-01-01 |
| EP3592741A1 (en) | 2020-01-15 |
| AU2018230236A1 (en) | 2019-10-31 |
| KR102582626B1 (ko) | 2023-09-22 |
| KR20190138793A (ko) | 2019-12-16 |
| RU2019131727A3 (enExample) | 2021-04-26 |
| US20210355117A1 (en) | 2021-11-18 |
| SG11201908322WA (en) | 2019-10-30 |
| IL269214B (en) | 2022-03-01 |
| EP3592741B1 (en) | 2023-02-15 |
| NZ757971A (en) | 2024-12-20 |
| TWI701246B (zh) | 2020-08-11 |
| MX2019010756A (es) | 2020-01-20 |
| JP2020510046A (ja) | 2020-04-02 |
| SG10202110112TA (en) | 2021-10-28 |
| CN111051304B (zh) | 2022-12-27 |
| WO2018163066A1 (en) | 2018-09-13 |
| CA3056030A1 (en) | 2018-09-13 |
| CN111051304A (zh) | 2020-04-21 |
| IL269214A (en) | 2019-11-28 |
| RU2019131727A (ru) | 2021-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102161364B1 (ko) | LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체 | |
| BR112019018688A2 (pt) | derivados de imidazo[4,5-c] quinolina como inibidores de lrrk2 | |
| EP3177624A1 (en) | Imidazopyridazine compounds | |
| CN108699080B (zh) | 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物 | |
| TWI675826B (zh) | 環狀經取代之咪唑并［４，５－ｃ］喹啉衍生物 | |
| RU2773516C2 (ru) | Новые производные имидазо[4,5-с]хинолина в качестве ингибиторов LRRK2 | |
| HK40058692A (en) | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | |
| HK40021310B (en) | Cyclic substituted imidazo[4,5-c]quinoline derivatives | |
| HK40021310A (en) | Cyclic substituted imidazo[4,5-c]quinoline derivatives | |
| HK40028779A (en) | Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors | |
| HK40028779B (en) | Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors | |
| HK1262295A1 (en) | 6,7-dihydro-5h-pyrazolo[5，1-b][1,3]oxazine-2-carboxamide compounds | |
| HK1258857B (en) | Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |